Table 1.

14-3-3σ immunostaining in relation to clinicopathological variables

Variables	Total	Cytoplasm				Nucleus				Cytoplasm and nucleus
	n	Low	High	(%)	p1	Low	High	(%)	p1	Low	High	(%)	p1
Age					0.21				0.96				0.06
25–69	121	39	82	(68)		49	72	(60)		38	83	(69)
70–84	147	34	113	(77)		62	85	(58)		28	119	(81)
85+	34	11	23	(68)		14	20	(59)		10	24	(71)
FIGO					0.26				0.49				0.08
Ia	11	2	9	(82)		4	7	(64)		2	9	(82)
Ib	37	16	21	(57)		19	18	(49)		16	21	(57)
II	110	28	82	(75)		43	67	(61)		22	88	(80)
III	121	32	89	(74)		46	75	(62)		30	91	(75)
IV	19	5	14	(74)		10	9	(47)		5	14	(74)
Not available	4
Lymph node metastasis					0.42				0.97				0.54
None	137	41	96	(70)		55	82	(60)		36	101	(74)
Unilateral	76	18	58	(76)		31	45	(59)		17	59	(78)
Bilateral	34	12	22	(65)		13	21	(62)		11	23	(68)
Not available	55
Tumour diameter (cm)					0.001				0.002				0.001
0.3–2.5	92	34	58	(63)		50	42	(46)		33	59	(64)
2.6–4.0	94	30	64	(68)		35	59	(63)		25	69	(73)
4.1–20.0	100	14	86	(86)		30	70	(70)		12	88	(88)
Not available	16
Tumor differentiation					0.09				0.10				0.08
Well	76	27	49	(65)		39	37	(49)		25	51	(67)
Moderate	154	43	111	(72)		61	93	(60)		39	115	(75)
Poor	72	14	58	(81)		25	47	(65)		12	60	(83)
Depth of invasion (mm)					0.01				0.001				0.007
0.0–4.0	80	32	48	(60)		45	35	(44)		30	50	(63)
4.1–8.0	99	24	75	(76)		38	61	(62)		21	78	(79)
8.1–40.0	112	24	88	(79)		34	78	(70)		21	91	(81)
Not available	11
Infiltration of vessel					0.33				0.50				0.41
No	233	67	166	(71)		99	134	(58)		61	172	(74)
Yes	66	15	51	(77)		25	41	(62)		14	52	(79)
Not available	3
p142					1.00				1.00				0.88
Low (-)	135	98	37	(27)		46	89	(66)		84	51	(38)
High (+)	77	56	21	(27)		26	51	(66)		49	28	(36)
Not available	100
p162					0.63				0.88				0.15
Low (< 5%)	148	40	108	(73)		51	97	(66)		37	111	(75)
High (≥ 5%)	63	15	48	(76)		21	42	(67)		10	53	(84)
Not available	91
p212					0.17				0.87				0.10
Low (-)	122	36	86	(71)		42	80	(66)		32	90	(74)
High (+)	90	19	71	(79)		30	60	(67)		15	75	(84)
Not available	90
p272					0.18				0.56				0.19
Low (< 50%)	164	39	125	(76)		54	110	(67)		33	131	(80)
High (≥ 50%)	48	16	32	(67)		18	30	(63)		14	34	(71)
Not available	90
p532					0.70				0.12				0.93
Low (< 5%)	93	25	68	(73)		26	67	(72)		20	73	(79)
High (≥ 5%)	118	29	89	(75)		45	73	(62)		26	92	(78)
Not available	91
Cyclin A2					0.68				0.09				0.59
Low (< 5%)	61	17	44	(72)		26	35	(57)		15	46	(75)
High (≥ 5%)	151	38	113	(75)		46	105	(70)		32	119	(79)
Not available	90
Cyclin D12					0.87				0.75				0.83
Low (-)	156	40	116	(74)		52	104	(67)		34	122	(78)
High (+)	56	15	41	(73)		20	36	(64)		13	43	(77)
Not available	90
Cyclin D32					0.25				0.76				0.69
Low (< 50%)	153	43	110	(72)		51	102	(67)		35	118	(77)
High (≥ 50%)	59	12	47	(80)		21	38	(64)		12	47	(80)
Not available	90
Cyclin E2					0.72				0.64				0.32
Low (< 50%)	173	44	129	(75)		60	113	(65)		36	137	(79)
High (≥ 50%)	39	11	28	(72)		12	27	(69)		11	28	(72)
Not available	90
HPV2					0.87				0.47				0.98
Low (-)	168	44	124	(74)		57	111	(66)		39	129	(77)
High (+)	44	11	33	(75)		15	29	(66)		8	36	(82)
Not available	90

¹ Pearson chi-square ² In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [28-31].